Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
p53 reactivator
DRUG CLASS:
p53 reactivator
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
APR-246 (18)
PC14586 (2)
APR-548 (1)
CP-31398 (0)
NSC59984 (0)
RITA (0)
APR-246 (18)
PC14586 (2)
APR-548 (1)
CP-31398 (0)
NSC59984 (0)
RITA (0)
›
Associations
(21)
News
Trials
VERI cancer hierarchy
Reset Filters
TP53 mutation
Myelodysplastic Syndrome
TP53 mutation
Myelodysplastic Syndrome
APR-246
Sensitive: B - Late Trials
APR-246
Sensitive
:
B
APR-246
Sensitive: B - Late Trials
APR-246
Sensitive
:
B
TP53 mutation
Acute Myelogenous Leukemia
TP53 mutation
Acute Myelogenous Leukemia
APR-246
Sensitive: B - Late Trials
APR-246
Sensitive
:
B
APR-246
Sensitive: B - Late Trials
APR-246
Sensitive
:
B
TP53 Y220C
Solid Tumor
TP53 Y220C
Solid Tumor
PC14586
Sensitive: B - Late Trials
PC14586
Sensitive
:
B
PC14586
Sensitive: B - Late Trials
PC14586
Sensitive
:
B
TP53 mutation
Non Small Cell Lung Cancer
TP53 mutation
Non Small Cell Lung Cancer
pembrolizumab + APR-246
Sensitive: C3 – Early Trials
pembrolizumab + APR-246
Sensitive
:
C3
pembrolizumab + APR-246
Sensitive: C3 – Early Trials
pembrolizumab + APR-246
Sensitive
:
C3
TP53 mutation
Solid Tumor
TP53 mutation
Solid Tumor
pembrolizumab + APR-246
Sensitive: C3 – Early Trials
pembrolizumab + APR-246
Sensitive
:
C3
pembrolizumab + APR-246
Sensitive: C3 – Early Trials
pembrolizumab + APR-246
Sensitive
:
C3
TP53 mutation
Acute Myelogenous Leukemia
TP53 mutation
Acute Myelogenous Leukemia
venetoclax + APR-246
Sensitive: C3 – Early Trials
venetoclax + APR-246
Sensitive
:
C3
venetoclax + APR-246
Sensitive: C3 – Early Trials
venetoclax + APR-246
Sensitive
:
C3
TP53 273H
Lung Cancer
TP53 273H
Lung Cancer
APR-246
Sensitive: D – Preclinical
APR-246
Sensitive
:
D
APR-246
Sensitive: D – Preclinical
APR-246
Sensitive
:
D
FGF4 amplification + HRAS Q61R + TP53 672+2T>G
Prostate Cancer
FGF4 amplification + HRAS Q61R + TP53 672+2T>G
Prostate Cancer
APR-246
Sensitive: D – Preclinical
APR-246
Sensitive
:
D
APR-246
Sensitive: D – Preclinical
APR-246
Sensitive
:
D
FGF3 amplification + HRAS Q61R + TP53 672+2T>G
Prostate Cancer
FGF3 amplification + HRAS Q61R + TP53 672+2T>G
Prostate Cancer
APR-246
Sensitive: D – Preclinical
APR-246
Sensitive
:
D
APR-246
Sensitive: D – Preclinical
APR-246
Sensitive
:
D
FGF19 amplification + HRAS Q61R + TP53 672+2T>G
Prostate Cancer
FGF19 amplification + HRAS Q61R + TP53 672+2T>G
Prostate Cancer
APR-246
Sensitive: D – Preclinical
APR-246
Sensitive
:
D
APR-246
Sensitive: D – Preclinical
APR-246
Sensitive
:
D
TP53 Y220C
Gastric Cancer
TP53 Y220C
Gastric Cancer
PC14586
Sensitive: D – Preclinical
PC14586
Sensitive
:
D
PC14586
Sensitive: D – Preclinical
PC14586
Sensitive
:
D
TP53 mutation
Esophageal Adenocarcinoma
TP53 mutation
Esophageal Adenocarcinoma
APR-246
Sensitive: D – Preclinical
APR-246
Sensitive
:
D
APR-246
Sensitive: D – Preclinical
APR-246
Sensitive
:
D
TP53 mutation
Acute Lymphocytic Leukemia
TP53 mutation
Acute Lymphocytic Leukemia
APR-246
Sensitive: D – Preclinical
APR-246
Sensitive
:
D
APR-246
Sensitive: D – Preclinical
APR-246
Sensitive
:
D
MYC amplification
Small Cell Lung Cancer
MYC amplification
Small Cell Lung Cancer
APR-246
Sensitive: D – Preclinical
APR-246
Sensitive
:
D
APR-246
Sensitive: D – Preclinical
APR-246
Sensitive
:
D
TP53 R248Q
Myelodysplastic Syndrome
TP53 R248Q
Myelodysplastic Syndrome
APR-246
Sensitive: D – Preclinical
APR-246
Sensitive
:
D
APR-246
Sensitive: D – Preclinical
APR-246
Sensitive
:
D
TP53 R248Q
Acute Myelogenous Leukemia
TP53 R248Q
Acute Myelogenous Leukemia
APR-246
Sensitive: D – Preclinical
APR-246
Sensitive
:
D
APR-246
Sensitive: D – Preclinical
APR-246
Sensitive
:
D
TP53 mutation
Triple Negative Breast Cancer
TP53 mutation
Triple Negative Breast Cancer
APR-246
Sensitive: D – Preclinical
APR-246
Sensitive
:
D
APR-246
Sensitive: D – Preclinical
APR-246
Sensitive
:
D
TP53 R280K + BRCA wild-type
Triple Negative Breast Cancer
TP53 R280K + BRCA wild-type
Triple Negative Breast Cancer
APR-246
Sensitive: D – Preclinical
APR-246
Sensitive
:
D
APR-246
Sensitive: D – Preclinical
APR-246
Sensitive
:
D
BRCA2 Y1655* + TP53 mutation
Ovarian Cancer
BRCA2 Y1655* + TP53 mutation
Ovarian Cancer
APR-246
Sensitive: D – Preclinical
APR-246
Sensitive
:
D
APR-246
Sensitive: D – Preclinical
APR-246
Sensitive
:
D
BRCA2 mutation + TP53 D816Y
Ovarian Cancer
BRCA2 mutation + TP53 D816Y
Ovarian Cancer
APR-246
Sensitive: D – Preclinical
APR-246
Sensitive
:
D
APR-246
Sensitive: D – Preclinical
APR-246
Sensitive
:
D
TP53 R175H
Prostate Cancer
TP53 R175H
Prostate Cancer
APR-548
Sensitive: D – Preclinical
APR-548
Sensitive
:
D
APR-548
Sensitive: D – Preclinical
APR-548
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login